Início/Ações/IXHL

IXHL

USD

Incannex Healthcare Inc. Common Stock

$0.339-0.005 (-1.480%)

Preço em tempo real

Healthcare

Drug Manufacturers - Specialty & Generic

Austrália

Gráfico de preços

Loading Chart...

Métricas-chave

Métricas de mercado

Fundamentos da empresa

Estatísticas de negociação

Métricas de mercado

Abertura

$0.344

Máximo

$0.349

Mínimo

$0.336

Volume

15.84M

Fundamentos da empresa

Capitalização de mercado

118.0M

Setor

Drug Manufacturers - Specialty & Generic

País

Australia

Estatísticas de negociação

Volume médio

66.44M

Bolsa de valores

NCM

Moeda

USD

Faixa de 52 semanas

Mínimo $0.08Atual $0.339Máximo $3.12

Notícias relacionadas

26/08/2025 · 12:00

GlobeNewswire

Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder

MELBOURNE, Australia and NEW YORK, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company") is pleased to report positive data from its Phase 2 clinical trial of PSX-001

Ver mais

Incannex Reports Positive Results from Phase 2 Clinical Trial of PSX-001 (Psi-GAD) for Generalised Anxiety Disorder

22/08/2025 · 12:00

GlobeNewswire

Incannex Healthcare Authorizes $20 Million Share Repurchase Program

MELBOURNE, Australia and NEW YORK, Aug. 22, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL) ("Incannex" or the "Company"), a clinical-stage biopharmaceutical company developing innovative combination

Ver mais

Incannex Healthcare Authorizes $20 Million Share Repurchase Program

8/08/2025 · 12:00

GlobeNewswire

Incannex Receives Positive Patient-Reported Outcomes and Compelling Phase 2 Efficacy Data for IHL-42X in Obstructive Sleep Apnoea

MELBOURNE, Australia and NEW YORK, Aug. 08, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (NASDAQ:IXHL), a clinical-stage pharmaceutical company developing innovative combination therapies for prevalent medical

Ver mais